Introduction
Nosocomial infections with Clostridium difficile often occur during antibiotic therapy. The C. difficile-associated diseases, namely antibiotic-associated diarrhoea and pseudomembranous colitis, are an increasing problem in health care, especially since hypervirulent strains (NAP1/027) have emerged recently . The pathogenicity of C. difficile is based upon the action of at least one of the two major exotoxins produced and secreted by the bacterium, named toxin A (TcdA) and toxin B (TcdB), which belong to the family of clostridial glucosylating toxins (Sullivan et al., 1982; Rifkin et al., 1977; Bartlett et al., 1977; Voth & Ballard, 2005; Just & Gerhard, 2004) . In addition, an actin-ADP-ribosylating toxin, CDT, has been identified in some strains of C. difficile, the pathological role of which is not clear so far (Popoff et al., 1988) . Notably, the hypervirulent strain NAP1/027 is characterized by production of large amounts of glucosylating toxins, resistance against fluoroquinolones and the presence of CDT (Warny et al., 2005) . Toxins A and B are encoded by tcdA and tcdB, which are positioned in a 19.6 kb pathogenicity locus. Three additional genes (tcdC, tcdD and tcdE) encoding negative (tcdC) and positive (tcdD) regulators as well as a holin-like pore-forming protein (tcdE) are part of this locus (Hammond & Johnson, 1995; Hundsberger et al., 1997; Mani & Dupuy, 2001) . Variations in the structure of the pathogenicity locus are the basis for more than 20 toxinotypes (Rupnik et al., 1997 (Rupnik et al., , 1998 Torres, 1991) . The emerging highly virulent C. difficile strain NAP1/027 is characterized by a deletion in the tcdC locus and this may cause high toxin A and B production .
A hallmark of these large protein toxins (toxin A, 308 kDa; toxin B, 269 kDa) is a modular, tripartite composition (von Eichel-Streiber et al., 1996; Jank et al., 2007b) . The Nterminal catalytic domain (aa 1-543), also called the 'A' domain, possesses full biological activity (Hofmann et al., 1997; Faust et al., 1998) . The C-terminal domain consists of repetitive oligopeptides, involved in receptor binding (Tucker & Wilkins, 1991; Wren, 1991; Frisch et al., 2003; Ho et al., 2005) . The central domain is by far the largest part of the proteins and is characterized by a small hydrophobic stretch (aa 956-1128) which is thought to mediate membrane insertion during translocation processes. The central 'translocation' domain and the Cterminal 'binding' domain are classically referred to as one unit, the 'B' domain (von Eichel-Streiber, 1992; Just & Gerhard, 2004) . Notably, only the N-terminal 'A' domain is translocated into the cytosol of target cells (Pfeifer et al., 2003; Rupnik et al., 2005) . Therefore, a controlled and limited proteolysis is an essential step in the uptake of clostridial glucosylating toxins.
Toxins A and B possess glucosyltransferase activity and inactivate Rho GTPases Intracellular targets of the bacterial glucosyltransferases are small GTPases of the Rho family (Just et al., 1995) , which comprise a family of about 20 GTP-binding proteins. Rho proteins function as molecular switches and are involved in multiple cellular signalling processes, including regulation of the actin cytoskeleton, adhesion, migration and cell polarity. They control enzyme activities, gene transcription, cell cycle progression and apoptosis (Etienne-Manneville & Hall, 2002) . The toxins catalyse the mono-O-glucosylation of the Rho GTPases at a threonine residue (Thr35/37), which is essential for the switch function of the GTPases (Just et al., 1995) . Glucosylation blocks the activation of Rho GTPases by their activators (guanine nucleotide exchange factors, GEFs), inhibits interaction with their effectors (e.g. protein kinases and adaptor proteins), blocks their membrane-cytosol cycling and favours membrane binding. The structural basis of the inhibiting effects on Rho functions is probably a blockade of the active conformation of Rho GTPases by glucosylation (Sehr et al., 1998; Vetter et al., 2000; Geyer et al., 2003) . This leads, amongst others, to the depolymerization of the actin cytoskeleton, cell rounding and finally apoptosis (Just & Gerhard, 2004; Voth & Ballard, 2005) .
N-terminus: the catalytic centre
The biologically active domain, which is delivered into the cytosol, comprises the first 543 aa . The recently solved 3D-structure of this fragment revealed that it was closely related to other bacterial glucosyltransferases belonging to the GT-A family . The catalytic core consists of 234 aa and is formed by a mixed a/b-fold with mostly parallel b-strands as the central part. The more than 300 additional residues are mainly helices, of which the first four N-terminal helices are most probably involved in membrane association, therefore assuring close proximity of the enzyme with its substrates. Characteristic for GT-A family members is the DXD motif involved in complexation of manganese ions, UDP and glucose. Mutation of these essential aspartate residues leads to inactivation of the toxin (Busch et al., 1998) . The cosubstrate for the bacterial glucosyltransferases is UDPglucose; only a-toxin from Clostridium novyi utilizes UDP-N-acetylglucosamine (UDP-GlcNAc) (Selzer et al., 1996) . This difference in cosubstrate specificity is based on sterical hindrance by bulky amino acids (e.g. Ile
383
/Gln 385 in toxin B) blocking the catalytic pocket for the larger UDPGlcNAc. In a-toxin, small serine and alanine residues at the corresponding positions allow UDP-GlcNAc to enter the catalytic cleft . Little is known so far about the molecular/structural determinants underlying the differences in substrate recognition by different glucosylating toxins. Based on crystallographic and biochemical data, a preliminary docking model has been proposed where the GTPases bind to the glucosyltransferases with the same consensus region and in a comparable manner to how they normally bind to effector molecules (Dvorsky & Ahmadian, 2004; Jank et al., 2007a) .
The C-terminal region mediates receptor binding
The C-terminus of the 'B' domain consists of clostridial repetitive oligopeptides, which are involved in receptor binding. The nature of the receptor has still not been solved, but there are hints for a role of carbohydrate structures in toxin binding. In the case of toxin A, binding to, for example, a galactose-and N-acetylglucosamine glucoprotein, a membranous sucrase-isomaltase glucoprotein and Gala1-3Galb1-4GlcNAc in different animal model systems has been reported (Rolfe & Song, 1993; Pothoulakis et al., 1996; Krivan et al., 1986; Tucker & Wilkins, 1991) . However, since these structures are absent in a wide variety of sensitive cells and also a-anomeric galactose bonds are absent in human tissue (Larsen et al., 1990) , these carbohydrate structures are unlikely to be or cannot be part of the intestinal receptor in humans. Nevertheless, the proposed role of carbohydrates was supported by the recently solved structure of two Cterminal fragments of toxin A and the co-crystallization of toxin A with an artificial trisaccharide (Ho et al., 2005; Greco et al., 2006) . These data showed that the C-terminus possesses a solenoid-like structure, consisting of 7 large repeats with 30 residues and 32 small repeats with 15-21 residues. The large and small peptide repeats have single b-hairpin structures with antiparallel b-strands of 5-6 residues. The b-hairpins are connected by loops of 7-10 residues in short repeats, and by 18 residues in long repeats. Each hairpin is rotated by 120u, resulting in a screw-like structure. However, since the identified amino acid residues participating in carbohydrate binding are not conserved in other clostridial glucosylating toxins, the receptor(s) still remains to be identified.
The central translocation domain
The large middle part of the protein toxins makes up more than 50 % of the total size, but little is known about its exact functions. It is characterized by a hydrophobic stretch which is most probably responsible for membrane penetration (transmembrane prediction) (von EichelStreiber et al., 1992) . Therefore, this region is referred to as the 'translocation domain'. Deletion studies proved the importance of the hydrophobic region for toxin activity (Barroso et al., 1994) . The same report also indicated a large impact of specific residues located inside the translocation domain but outside the hydrophobic region on the cytotoxic activity of the protein. For example, exchange of cysteine 698 to serine or histidine 653 to glutamine in toxin B reduced the cytotoxic titre by about 90 or 99 %, respectively. At that time, no molecular explanation for these observations was available, but it was already proposed that these residues may be involved in the uptake and processing of the toxins.
Uptake of clostridial glucosylating toxins
Clostridial glucosylating toxins enter eukaryotic target cells according to the 'short trip model' of bacterial exotoxin uptake (Sandvig et al., 2004) . Following receptor-mediated endocytosis, the acidification of early endosomes by the vesicular H + -ATPase induces a conformational change characterized by an increase in hydrophobicity (Florin & Thelestam, 1983; Barth et al., 2001; Qa'Dan et al., 2000) . This is probably due to a surface exposure of the hydrophobic region, which then enables the corresponding part of the toxin to insert into the membrane and to build a pore through which the catalytic domain can translocate into the cytosol. Pore formation under acidic conditions has been demonstrated for C. difficile toxin A and toxin B (Barth et al., 2001; Giesemann et al., 2006) . As mentioned above, solely the N-terminal catalytic domain (aa 1-543) is then released from the early endosomes and reaches the cytosol of eukaryotic cells. This translocation of the 'A' domain across the cellular membrane and the release into the cytosol still remains enigmatic. One essential step is the secession of the first 543 aa from the protein under controlled conditions. Where this separation takes place is not clear, neither is the exact nature of the proteolytic activity involved in this process. Just recently, it was demonstrated that this cutting may be accomplished by an intrinsic activity of the toxin itself. Two independent studies identified autoproteolysis activated by dithiothreitol (DTT) and/or myo-inositol hexakisphosphate (InsP 6 ). One of these studies ascribed the function to a putative aspartate protease domain located in the C-terminal part of the translocation domain (Reineke et al., 2007) . The second study reports that the proteolytic activity is based on an intrinsic cysteine protease domain (CPD) located adjacent to the autocleavage site in the N-terminal part of the translocation domain (Egerer et al., 2007) .
Identification and biochemical characterization of an intrinsic CPD
The primary sequence of toxin B aa 544-955, a fragment bordered by the N-terminal glucosyltransferase domain ('GT') and the hydrophobic, putative transmembrane region ('HR', aa 956-1128; see Fig. 1 , upper panel) displays a striking sequence similarity to repeat in toxin (RTX) protein toxins and autotransporter adhesins from, for example, Vibrio cholerae and Vibrio vulnificus/Vibrio splendidus. Although overall similarity is relatively low, ranging from 23 to 25 %, the sequence identities concentrate in specific clusters resembling a putative catalytic triad of a cysteine protease (see Fig. 1 ). This assumption is strengthened by the recent identification and characterization of the corresponding intrinsic CPD within V. cholerae RTX (Sheahan et al., 2007) .
According to the prediction of an intrinsic proteolytic activity, the degradation of the holotoxin into GT domain and binding/translocation domain can be induced by factors and/or conditions as found in the cytosol. For example, under reducing conditions, toxin A and toxin B show a split product at about 63 kDa, a size corresponding to the isolated N-terminal glucosyltransferase domain. MALDI-TOF analysis confirmed the expected degradation of the holotoxin into the corresponding domains. The onset of autoproteolysis under the influence of DTT points to an intramolecular disulfide bond within toxin B implicated in the regulation of the CPD.
Data that clearly indicate an essential role of cysteine residues in this process come from the utilization of Nethylmaleimide (NEM), a common inhibitor of cysteine proteases. When NEM is added after onset of proteolytic cleavage achieved by low DTT concentrations, further degradation is inhibited.
InsP 6 induces autoproteolysis of toxin B in a comparable manner, but InsP 6 is more efficient than DTT. Proteolysis starts at lower concentrations and is faster compared to proteolysis with DTT. Interestingly, when varying concen- Recombinant toxin B and the point mutant C698A were produced as recombinant glutathione S-transferase fusion proteins as described by Egerer et al. (2007) . Wild-type recombinant toxin B displays limited proteolysis during purification, which is absent in the C698A mutant (see Coomassie-stained SDS-PAGE gels, upper panel). For cell intoxication, HeLa cells were cultivated in Dulbecco's minimal Eagle's medium in 12-well cell culture dishes. Recombinant toxin B (rec. toxin B) and toxin B point mutant (C698A) (1 mg ml "1 ) were applied for 4-6 h at 37 6C. Wild-type toxin B induced complete cell rounding within 4-5 h. The C698A mutant showed a significantly diminished cytotoxic potential.
Processing of Clostridium difficile toxins
show no degradation at all, whereas toxin B 1-955 D587N is not completely insensitive to degradation. This is probably based on other aspartate and glutamine residues neighbouring D587 which can in part substitute D587 in the catalytic triad. Notably, exchange of an unrelated cysteine (C595) has no stabilizing effect and the mutation of the autocleavage site (L 543 /G 544 ) results in a stabilized protein comparable to the catalytic triad point mutants.
Autoproteolysis is essential for the cytotoxic potential of toxin B. When the catalytic cysteine 698 is mutated in recombinant holotoxin, the corresponding toxin variant is stabilized (comparable to toxin B 1-955 C698A) and loses its cytotoxicity almost completely. This effect is in line with former observations concerning toxin B mutagenesis (Barroso et al., 1994) .
These data (summarized in Fig. 2 ; see also Egerer et al., 2007) indicate that the translocation domain of clostridial glucosylating toxins comprises a CPD. This intrinsic activity is responsible for the autocatalytic processing of the toxins. The proteolysis, which is essential for cytotoxic activity, is activated by reducing conditions and/or InsP 6 .
Conclusions
C. difficile toxins are large multidomain proteins. Their action depends on a complex uptake mechanism including proteolytic processing (Aktories, 2007) . Although the theoretical model of toxin uptake (schematically outlined in Fig. 3 ) is generally accepted (Sandvig et al., 2004) , the precise molecular mechanisms have not been well characterized. However, a major step forward was made with the finding of an intrinsic proteolytic activity of the toxins. This autoproteolytic activity is induced by InsP 6 and/or DTT and is responsible for the separation of the catalytic domain from the holotoxin (Reineke et al., 2007; Egerer et al., 2007) . These findings are in line with reports on RTX toxin from V. cholerae, which also undergoes autocatalytic processing during uptake (Sheahan et al., 2007) . The striking similarity between clostridial glucosylating toxins and RTX toxins is limited to the CPD of RTX and concentrates around the putative catalytic residues, e.g. D 587 H 653 C 698 of toxin B. The importance of these residues for autocatalytic processing was shown by site-directed mutagenesis. Notably, these residues are conserved in all clostridial glucosylating toxins. Processing does not require the holotoxin, but is also detectable with fragments comprising only the first 955 aa. This suggests against the hypothesis of an intrinsic aspartate protease domain located around a DXG motif at position D 1665 in close vicinity to the C-terminal polypeptide repeats domain (Reineke et al., 2007) . In this context, it is noteworthy that the DXG motif is absent in C. novyi a-toxin, although this toxin is also autocatalytically cleaved under the same conditions. Furthermore, the localization of the CPD in toxin B adjacent to the GT domain is comparable to the CPD flanking the actin-cross-linking domain in RTX toxins. Since, in the case of toxin B, InsP 6 seems to be the physiologically relevant inducer of autoproteolysis, this close proximity of the CPD and GT domain makes sense with regard to the uptake process (see Fig. 3 ). Here, a cotranslocation of the GT domain and the CPD would guarantee access of the CPD to cytosolic InsP 6 and therefore a controlled onset of proteolysis after complete translocation. The exact role of InsP 6 in this process is still unclear, but since this highly charged, multifunctional molecule seems to have diverse structural effects, an impact on the stability by modulation of toxin conformation seems to be a plausible assumption (Shears, 2001) .
Considering the fast propagation of severe nosocomial infections with hypervirulent strains of C. difficile, new strategies for therapy are needed (Bartlett & Perl, 2005) . Since the pathogenicity of C. difficile depends on its glucosylating protein toxins and severity seems to correlate with toxin amount, these molecules may be targets for therapeutic strategies. Development of glycan-mimicking compounds blocking the receptor-binding domain is a potential approach (Greco et al., 2006) . Moreover, the 3D-structure of the catalytic domain of various glucosyltransferases may allow the design of membrane-permeable inhibitors targeting the catalytic domain . In any case, further progress in understanding the molecular mechanisms involved in the actions of C. difficile toxins will certainly provide new perspectives for development of new strategies against the pathogen and its toxins.
